Investigational New Drugs

3.6k papers and 80.0k indexed citations i.

About

The 3.6k papers published in Investigational New Drugs in the last decades have received a total of 80.0k indexed citations. Papers published in Investigational New Drugs usually cover Oncology (1.9k papers), Molecular Biology (1.6k papers) and Pulmonary and Respiratory Medicine (910 papers) specifically the topics of Cancer Treatment and Pharmacology (494 papers), Cancer therapeutics and mechanisms (446 papers) and Lung Cancer Treatments and Mutations (410 papers). The most active scholars publishing in Investigational New Drugs are Stephanie Green, Geoffrey R. Weiss, Jan H.M. Schellens, Adrian M. Senderowicz, Slawomir Wojtowicz‐Praga, Jos H. Beijnen, Jaap Verweij, Michael Hawkins, Robert B. Dickson and Daniel D. Von Hoff.

In The Last Decade

Fields of papers published in Investigational New Drugs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers published in Investigational New Drugs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers published in Investigational New Drugs.

Countries where authors publish in Investigational New Drugs

Since Specialization
Citations

This map shows the geographic impact of research published in Investigational New Drugs. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers published in Investigational New Drugs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Investigational New Drugs more than expected).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar’s output or impact.

Explore journals with similar magnitude of impact

Rankless by CCL
2025